

# Karen E Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3393789/publications.pdf>

Version: 2024-02-01

17  
papers

1,470  
citations

758635

12  
h-index

887659

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

814  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 40.	3.8	327
2	Randomized controlled trial of deutetrabenazine for tardive dyskinesia. <i>Neurology</i> , 2017, 88, 2003-2010.	1.5	296
3	Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Psychiatry</i> , 2017, 4, 595-604.	3.7	291
4	Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1411-1418.	0.9	237
5	Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. <i>American Journal of Psychiatry</i> , 2016, 173, 184-192.	4.0	106
6	Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. <i>Journal of Huntington's Disease</i> , 2018, 7, 355-366.	0.9	58
7	An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease. <i>PLOS Currents</i> , 2011, 3, RRN1261.	1.4	40
8	Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-319918.	0.9	25
9	Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2016, 5, 389-394.	0.9	18
10	Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. <i>Patient</i> , 2018, 11, 547-559.	1.1	17
11	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients: A Randomized Phase 2 Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3682.	1.0	15
12	The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study. <i>Clinical Genetics</i> , 2019, 96, 28-34.	1.0	14
13	Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. <i>Patient</i> , 2017, 10, 541-544.	1.1	10
14	Quality of Care for Huntington's Disease in the United States: Findings from a National Survey of Patients and Caregivers. <i>Journal of Huntington's Disease</i> , 2019, 8, 509-519.	0.9	8
15	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. <i>Frontiers in Neurology</i> , 2021, 12, 595679.	1.1	6
16	The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. <i>Journal of Huntington's Disease</i> , 2019, 8, 435-441.	0.9	1
17	Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. <i>Frontiers in Neurology</i> , 2022, 13, 773999.	1.1	1